CN Patent

CN106632564B — 奥贝胆酸盐及其无定形物和药物组合物

Assigned to Suzhou Zelgen Biopharmaceutical Co Ltd · Expires 2021-04-13 · 5y expired

What this patent protects

本发明涉及奥贝胆酸盐及其无定形物，更具体地，涉及奥贝胆酸钠盐、钾盐、镁盐和钙盐及其无定形物。所述奥贝胆酸盐的无定形物适合用于制备法尼醇X受体(Farnesoid X Receptor，FXR)激动剂的药物及其组合物，可用于治疗或预防非酒精性脂肪肝炎、非酒精性脂肪肝病、胆结石、原发性胆汁性肝硬化、肝硬化，降低胆固醇和甘油三酯等。

USPTO Abstract

本发明涉及奥贝胆酸盐及其无定形物，更具体地，涉及奥贝胆酸钠盐、钾盐、镁盐和钙盐及其无定形物。所述奥贝胆酸盐的无定形物适合用于制备法尼醇X受体(Farnesoid X Receptor，FXR)激动剂的药物及其组合物，可用于治疗或预防非酒精性脂肪肝炎、非酒精性脂肪肝病、胆结石、原发性胆汁性肝硬化、肝硬化，降低胆固醇和甘油三酯等。

Drugs covered by this patent

Patent Metadata

Patent number
CN106632564B
Jurisdiction
CN
Classification
—
Expires
2021-04-13
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Zelgen Biopharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.